Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON28180
NL-OMON28180
Recruiting
Not Applicable

Identification of pediatric Hodgkin lymphoma biomarkers and novel therapeutic targets

Erasmus MC - Sophia0 sites320 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPediatric Hodgkin lymphoma

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pediatric Hodgkin lymphoma
Sponsor
Erasmus MC - Sophia
Enrollment
320
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational non invasive

Investigators

Sponsor
Erasmus MC - Sophia

Eligibility Criteria

Inclusion Criteria

  • •Hodgkin lymphoma group
  • •In order to be eligible to participate in the Hodgkin lymphoma group, a subject must meet all of the following criteria:
  • •\-? Diagnosis of classical Hodgkin Lymphoma confirmed by reference pathology
  • •\-? Patient aged below 18 at time of diagnosis
  • •\-? Treatment according the European Network of Paediatric Hodgkin\`s Lymphoma Second International Inter\-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents (EuroNet\-PHL\-C2\) protocol or treatment for relapsed or refractory patients.
  • •\-? Written informed consent of the patient and/or the patient's parents or guardians according to national laws
  • •Control Group
  • •In order to be eligible to participate in the control group a subject must meet all of the following criteria:
  • •\-? No diagnosis of classical Hodgkin Lymphoma confirmed by reference pathology
  • •\-? Patient aged below 18 at time of diagnosis

Exclusion Criteria

  • •A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • •\-? HIV positivity
  • •\-? Other underlying immunologic disorders, with the exception of Epstein Barr Virus

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Identification of paediatric Hodgkin lymphoma biomarkers and novel therapeutic targets.Hodgkin diseaseHodgkin lymphomamalignant lymphoma10025319
NL-OMON54726Erasmus MC, Universitair Medisch Centrum Rotterdam230
Active, not recruiting
Phase 1
EuroNet-Paediatric Hodgkin?s Lymphoma Group First international Inter-Group Studyfor nodular lymphocyte-predominant Hodgkin?s Lymphoma in Children and Adolescents - EuroNet-PHL-LP1
EUCTR2007-004092-19-NLMartin Luther University of Halle/Wittenberg
Active, not recruiting
Phase 1
EuroNet-Paediatric Hodgkin’s Lymphoma Group First international Inter-Group Studyfor nodular lymphocyte-predominant Hodgkin’s Lymphoma in Children and Adolescents - EuroNet-PHL-LP1The first line therapy for childhood nodular lymphocyte-predominant Hodgkin’s lymphoma shall be further optimised to avoid over-treatment and decrease long-term complications.
EUCTR2007-004092-19-CZMartin Luther University of Halle/Wittenberg250
Active, not recruiting
Phase 1
Evaluation of the therapy of Hodgkin’s Lymphoma in Children and Adolescents
EUCTR2007-004092-19-DEMartin Luther University of Halle/Wittenberg200
Active, not recruiting
Phase 1
EuroNet-Paediatric Hodgkin’s Lymphoma Group First international Inter-Group Studyfor nodular lymphocyte-predominant Hodgkin’s Lymphoma in Children and Adolescents - EuroNet-PHL-LP1The first line therapy for childhood nodular lymphocyte-predominant Hodgkin’s lymphoma shall be further optimised to avoid over-treatment and decrease long-term complications.
EUCTR2007-004092-19-ATMartin Luther University of Halle/Wittenberg250